Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure
Authors
Keywords
-
Journal
HYPERTENSION RESEARCH
Volume 40, Issue 6, Pages 535-540
Publisher
Springer Nature
Online
2017-01-19
DOI
10.1038/hr.2016.193
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis
- (2016) Christian Sonesson et al. Cardiovascular Diabetology
- Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design
- (2016) Jagdeep S. S. Singh et al. Cardiovascular Diabetology
- Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers
- (2016) H. J. L. Heerspink et al. DIABETES OBESITY & METABOLISM
- Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials
- (2016) A. Salsali et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
- (2016) F. Zaccardi et al. DIABETES OBESITY & METABOLISM
- The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes
- (2016) David Cherney et al. DIABETOLOGIA
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- (2016) T. D. Filippatos et al. EXPERT OPINION ON PHARMACOTHERAPY
- A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats
- (2016) Yui Takeshige et al. HYPERTENSION RESEARCH
- To overcome two diseases with one pill
- (2016) Masaki Mogi et al. HYPERTENSION RESEARCH
- Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of Type 2 diabetes
- (2016) Kouichi Tamura et al. HYPERTENSION RESEARCH
- A role for circadian clock in metabolic disease
- (2016) Ippei Shimizu et al. HYPERTENSION RESEARCH
- Circadian blood pressure changes and cardiovascular risk in elderly-treated hypertensive patients
- (2016) Sante D Pierdomenico et al. HYPERTENSION RESEARCH
- Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome
- (2016) Asadur Rahman et al. JOURNAL OF HYPERTENSION
- OS 12-03 SGLT-2-INHIBITION WITH DAPAGLIFLOZIN REDUCES TISSUE SODIUM CONTENT
- (2016) Roland Schmieder et al. JOURNAL OF HYPERTENSION
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks
- (2016) Lawrence Blonde et al. POSTGRADUATE MEDICINE
- Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study
- (2016) Michael A Weber et al. Lancet Diabetes & Endocrinology
- Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
- (2015) Hiroaki Iijima et al. ADVANCES IN THERAPY
- Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension
- (2015) N. B. Amin et al. DIABETES OBESITY & METABOLISM
- Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
- (2015) R. Chilton et al. DIABETES OBESITY & METABOLISM
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- 23Na Magnetic Resonance Imaging of the Lower Leg of Acute Heart Failure Patients during Diuretic Treatment
- (2015) Matthias Hammon et al. PLoS One
- The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
- (2014) David ZI Cherney et al. Cardiovascular Diabetology
- Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
- (2014) Bowen Lin et al. Cardiovascular Diabetology
- Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study
- (2014) Yutaka Seino et al. CURRENT MEDICAL RESEARCH AND OPINION
- Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
- (2014) Ilkka Tikkanen et al. DIABETES CARE
- SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats
- (2014) Masanori Yokono et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Chapter 7. Hypertension complicated by other diseases
- (2014) HYPERTENSION RESEARCH
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
- (2014) Aurora Merovci et al. JOURNAL OF CLINICAL INVESTIGATION
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors
- (2014) Raymond V. Oliva et al. Journal of the American Society of Hypertension
- Insulin resistance and hyperglycaemia in cardiovascular disease development
- (2014) Markku Laakso et al. Nature Reviews Endocrinology
- Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial
- (2013) Bruce Neal et al. AMERICAN HEART JOURNAL
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
- (2013) H. J. Lambers Heerspink et al. DIABETES OBESITY & METABOLISM
- 23 Na Magnetic Resonance Imaging-Determined Tissue Sodium in Healthy Subjects and Hypertensive Patients
- (2013) Christoph Kopp et al. HYPERTENSION
- Sodium-retaining effect of insulin in diabetes
- (2012) Michael W. Brands et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Circadian Pattern of Ambulatory Blood Pressure in Hypertensive Patients With and Without Type 2 Diabetes
- (2012) Diana E. Ayala et al. CHRONOBIOLOGY INTERNATIONAL
- Effects of Restricted Fructose Access on Body Weight and Blood Pressure Circadian Rhythms
- (2012) Danielle Senador et al. Experimental Diabetes Research
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Serum Uric Acid, Inflammation, and Nondipping Circadian Pattern in Essential Hypertension
- (2012) Osman Turak et al. Journal of Clinical Hypertension
- Sodium and Its Multiorgan Targets
- (2011) Edward D. Frohlich et al. CIRCULATION
- Visceral Fat Accumulation Is Associated With Circadian Blood Pressure in Japanese Patients With Impaired Glucose Tolerance
- (2011) T. Masaki et al. DIABETES CARE
- Circadian Rhythms and Metabolic Syndrome
- (2010) Eleonore Maury et al. CIRCULATION RESEARCH
- Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
- (2010) E. Ferrannini et al. DIABETES CARE
- Mechanisms of obesity-induced hypertension
- (2010) Vasilios Kotsis et al. HYPERTENSION RESEARCH
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
- (2010) Clifford J Bailey et al. LANCET
- Prevalence and Factors Associated With Circadian Blood Pressure Patterns in Hypertensive Patients
- (2009) Alejandro de la Sierra et al. HYPERTENSION
- Non-dipping pattern in ambulatory blood pressure monitoring is associated with metabolic abnormalities in a random sample of middle-aged subjects
- (2009) Olavi Ukkola et al. HYPERTENSION RESEARCH
- Night–day blood pressure ratio and dipping pattern as predictors of death and cardiovascular events in hypertension
- (2009) R H Fagard et al. JOURNAL OF HUMAN HYPERTENSION
- Ambulatory Blood Pressure Is a Better Marker Than Clinic Blood Pressure in Predicting Cardiovascular Events in Patients With/Without Type 2 Diabetes
- (2008) K. Eguchi et al. AMERICAN JOURNAL OF HYPERTENSION
- Lifetime Risk of Cardiovascular Disease Among Individuals With and Without Diabetes Stratified by Obesity Status in the Framingham Heart Study
- (2008) C. S. Fox et al. DIABETES CARE
- Association between circadian rhythm of blood pressure and glucose tolerance status in normotensive, non-diabetic subjects
- (2008) Lina Li et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Paget's Disease of the Mandible
- (2008) Mayank B. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
- (2008) William Duckworth et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now